Refine
Year of publication
- 2021 (2) (remove)
Document Type
- Part of a Book (2) (remove)
Language
- English (2)
Has Fulltext
- no (2) (remove)
Is part of the Bibliography
- yes (2)
Keywords
- Blockchain (1)
- Industry Use cases (1)
Institute
- Fakultät Elektrotechnik, Medizintechnik und Informatik (EMI) (ab 04/2019) (2) (remove)
Open Access
- Closed (1)
- Closed Access (1)
Digital transformation strengthens the interconnection of companies in order to develop optimized and better customized, cross-company business models. These models require secure, reliable, and traceable evidence and monitoring of contractually agreed information to gain trust between stakeholders. Blockchain technology using smart contracts allows the industry to establish trust and automate cross-company business processes without the risk of losing data control. A typical cross-company industry use case is equipment maintenance. Machine manufacturers and service providers offer maintenance for their machines and tools in order to achieve high availability at low costs. The aim of this chapter is to demonstrate how maintenance use cases are attempted by utilizing hyperledger fabric for building a chain of trust by hardened evidence logging of the maintenance process to achieve legal certainty. Contracts are digitized into smart contracts automating business that increase the security and mitigate the error-proneness of the business processes.
Dementia is a clinical diagnosis reflecting many possible underlying pathologies, for example, vascular dementia and neurodegenerative disorders such as frontotemporal dementia, Lewy body-type disorder or Alzheimer’s disease (AD). The breakthrough of 99mtechnetium-labelled perfusion tracers in the 1990s resulted in many SPECT studies of flow changes in AD. In the first decade of 2000, the role of perfusion SPECT was shifted from diagnosis towards differential diagnosis, parallel to the growing attention for diagnosing early stages of dementia. Previously a diagnosis based largely on a process of exclusion, new guidelines have emerged increasingly employing positive criteria to establish the diagnosis, including neuroimaging biomarkers. Nowadays, FDG PET has largely limited the role of perfusion SPECT, although it is still considered a valuable and cost-effective alternative when PET is not available.